ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
m931392
|
4.1K |
1.9M |
2 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
m931392
|
4.1K |
1.9M |
2 |
05/06/24 |
05/06/24 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
BIO International Convention
|
|
m931392
|
49 |
17K |
2 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
49
|
17K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Charlie and the once in a lifetime post!
|
|
m931392
|
52 |
17K |
2 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
52
|
17K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Charlie and the once in a lifetime post!
|
|
m931392
|
52 |
17K |
0 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
52
|
17K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
m931392
|
4.1K |
1.9M |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
4.1K
|
1.9M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
m931392
|
4.1K |
1.9M |
0 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Type D Response Submitted and Received by the US FDA
|
|
m931392
|
46 |
16K |
1 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
46
|
16K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
0 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
495
|
171K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
0 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
495
|
171K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
1 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
495
|
171K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
3 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
495
|
171K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
0 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
495
|
171K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Where we at?
|
|
m931392
|
495 |
171K |
0 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
495
|
171K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
m931392
|
670 |
254K |
0 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
670
|
254K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR to present at NWR Healthcare Conference
|
|
m931392
|
54 |
17K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
54
|
17K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR to present at NWR Healthcare Conference
|
|
m931392
|
54 |
17K |
2 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
54
|
17K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR to present at NWR Healthcare Conference
|
|
m931392
|
54 |
17K |
1 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
54
|
17K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR to present at NWR Healthcare Conference
|
|
m931392
|
54 |
17K |
0 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
54
|
17K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
IPPS and the most important membrane
|
|
m931392
|
19 |
8.1K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
19
|
8.1K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
m931392
|
670 |
254K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
670
|
254K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
OARSI 2024
|
|
m931392
|
92 |
39K |
2 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
92
|
39K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
OARSI 2024
|
|
m931392
|
92 |
39K |
0 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
92
|
39K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
How would involvement from a Venture capitalists or Private equity group look for Paradigm
|
|
m931392
|
59 |
17K |
0 |
25/02/24 |
25/02/24 |
ASX - By Stock
|
59
|
17K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
How would involvement from a Venture capitalists or Private equity group look for Paradigm
|
|
m931392
|
59 |
17K |
5 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
59
|
17K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
How would involvement from a Venture capitalists or Private equity group look for Paradigm
|
|
m931392
|
59 |
17K |
0 |
23/02/24 |
23/02/24 |
ASX - By Stock
|
59
|
17K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial
|
|
m931392
|
31 |
10K |
2 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
31
|
10K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
2 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
327
|
104K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
1 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
327
|
104K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
3 |
19/02/24 |
19/02/24 |
ASX - By Stock
|
327
|
104K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
OARSI 2024
|
|
m931392
|
92 |
39K |
5 |
18/02/24 |
18/02/24 |
ASX - By Stock
|
92
|
39K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
327
|
104K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
327
|
104K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
0 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
327
|
104K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
8 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
327
|
104K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
1 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
327
|
104K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
2 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
327
|
104K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Appoints Business Development Consultant
|
|
m931392
|
327 |
104K |
1 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
327
|
104K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial
|
|
m931392
|
59 |
21K |
1 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
59
|
21K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial
|
|
m931392
|
59 |
21K |
0 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
59
|
21K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial
|
|
m931392
|
59 |
21K |
1 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
59
|
21K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund
|
|
m931392
|
52 |
16K |
2 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
52
|
16K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund
|
|
m931392
|
52 |
16K |
0 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
52
|
16K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
IPPS
|
|
m931392
|
14 |
4.5K |
1 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
14
|
4.5K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
IPPS
|
|
m931392
|
14 |
4.5K |
0 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
14
|
4.5K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
m931392
|
236 |
78K |
2 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
236
|
78K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
m931392
|
236 |
78K |
2 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
236
|
78K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
m931392
|
236 |
78K |
4 |
03/02/24 |
03/02/24 |
ASX - By Stock
|
236
|
78K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
m931392
|
236 |
78K |
6 |
01/02/24 |
01/02/24 |
ASX - By Stock
|
236
|
78K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
m931392
|
236 |
78K |
1 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
236
|
78K
|
1
|
|